Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.

[1]  S. Gettinger,et al.  PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? , 2016, Clinical Cancer Research.

[2]  D. Carbone,et al.  Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  W. Cooper,et al.  The Role of Tumor‐Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[5]  S. Gettinger,et al.  CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. , 2016 .

[6]  Philip J. Stephens,et al.  Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. , 2016 .

[7]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[8]  Drew M. Pardoll,et al.  PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. , 2016, The New England journal of medicine.

[9]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[10]  Haiyi Jiang,et al.  Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve patients (pts) with EGFR mutant NSCLC: 57O , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  J. Ahn,et al.  Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.

[12]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[13]  Yun Dai,et al.  Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. , 2015, Clinical lung cancer.

[14]  P. Jänne,et al.  16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) , 2015 .

[15]  Thomas J. Smith,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jun Wu,et al.  Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis. , 2015, International journal of clinical and experimental pathology.

[17]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  Ge Li,et al.  The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs , 2015, Oncotarget.

[19]  R. Herbst,et al.  Objective measurement and clinical significance of TILs in non-small cell lung cancer. , 2015, Journal of the National Cancer Institute.

[20]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[21]  A. Chella,et al.  PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients , 2014, British Journal of Cancer.

[22]  B. Cho,et al.  Immunotherapy in the treatment of non-small cell lung cancer. , 2014, Lung cancer.

[23]  Y. Nakanishi,et al.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  S. Gettinger,et al.  Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. , 2014 .

[25]  A. Anderson.  Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape , 2014, Cancer Immunology Research.

[26]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[27]  Travis J Cohoon,et al.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. , 2013, Cancer discovery.

[28]  Lifen Gao,et al.  Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. , 2012, American journal of clinical pathology.

[29]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[30]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[31]  B. Lu,et al.  TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression , 2012, PloS one.

[32]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[33]  C. Cohen,et al.  Epstein-Barr Virus (EBV)-Encoded RNA: Automated In-Situ Hybridization (ISH) Compared with Manual ISH and Immunohistochemistry for Detection of EBV in Pediatric Lymphoproliferative Disorders , 2009, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[34]  E B Cox,et al.  Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.

[35]  Thomas J. Smith,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.